Education
About Us
Working with TipRanks
Follow Us
Tetralogic Pharma (TLOG)
OTHER OTC:TLOG
TLOG Stock Chart & Stats
Day’s Range― - ―
52-Week Range<$0.01 - $0.01
Previous CloseN/A
Volume107.58K
Average Volume (3M)N/A
Market Cap
$2.45K
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta-13.08
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding24,465,000
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
0.02% Other Institutional Investors
99.98% Public Companies and
Individual Investors
TLOG FAQ
What was Tetralogic Pharma’s price range in the past 12 months?
Tetralogic Pharma lowest stock price was <$0.01 and its highest was $0.01 in the past 12 months.
What is Tetralogic Pharma’s market cap?
Tetralogic Pharma’s market cap is $2.45K.
When is Tetralogic Pharma’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Tetralogic Pharma’s earnings last quarter?
Currently, no data Available
Is Tetralogic Pharma overvalued?
According to Wall Street analysts Tetralogic Pharma’s price is currently Overvalued.
Does Tetralogic Pharma pay dividends?
Tetralogic Pharma does not currently pay dividends.
What is Tetralogic Pharma’s EPS estimate?
Tetralogic Pharma’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Tetralogic Pharma have?
Tetralogic Pharma has 24,465,000 shares outstanding.
What happened to Tetralogic Pharma’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Tetralogic Pharma?
Currently, no hedge funds are holding shares in TLOG
Company Description
Tetralogic Pharma
TetraLogic Pharmaceuticals Corporation, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics in oncology and infectious diseases. It has two clinical-stage product candidates in development, such as birinapant and SHAPE. Birinapant is a small molecule therapeutic that mimics Second Mitochondrial Activator of Caspases-mimetic, which leads to apoptosis or cell-death in damaged cells. SHAPE is its proprietary histone deacetylase inhibitor for topical use for the treatment of early-stage cutaneous T-cell lymphoma. TetraLogic Pharmaceuticals Corporation has research collaboration with Walter and Eliza Hall Institute of Medical Research to examine SMAC-mimetics, including birinapant in the treatment of infectious disease. The company was formerly known as Gentara Corporation and changed its name to TetraLogic Pharmaceuticals Corporation in January 2006. TetraLogic Pharmaceuticals Corporation was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.
Biodexa Pharmaceuticals
―
Processa Pharmaceuticals
―
GRI Bio
―
Ocean Biomedical
―
Onconetix
―